MA50509A - Agonistes de triazole fusionnés du récepteur apj - Google Patents

Agonistes de triazole fusionnés du récepteur apj

Info

Publication number
MA50509A
MA50509A MA050509A MA50509A MA50509A MA 50509 A MA50509 A MA 50509A MA 050509 A MA050509 A MA 050509A MA 50509 A MA50509 A MA 50509A MA 50509 A MA50509 A MA 50509A
Authority
MA
Morocco
Prior art keywords
apj receptor
receptor fused
fused triazole
agonists
triazole agonists
Prior art date
Application number
MA050509A
Other languages
English (en)
Inventor
Paul John Dransfield
James S Harvey
Zhihua Ma
Ankit Sharma
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA50509A publication Critical patent/MA50509A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA050509A 2017-11-03 2018-10-25 Agonistes de triazole fusionnés du récepteur apj MA50509A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762581078P 2017-11-03 2017-11-03
US201862662516P 2018-04-25 2018-04-25

Publications (1)

Publication Number Publication Date
MA50509A true MA50509A (fr) 2021-06-02

Family

ID=64362636

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050509A MA50509A (fr) 2017-11-03 2018-10-25 Agonistes de triazole fusionnés du récepteur apj

Country Status (4)

Country Link
US (1) US11149040B2 (fr)
EP (1) EP3704122B1 (fr)
MA (1) MA50509A (fr)
WO (1) WO2019089335A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10689367B2 (en) * 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
MA52487A (fr) 2018-05-01 2021-03-10 Amgen Inc Pyrimidinones substituées en tant qu'agonistes du récepteur apj

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DE3334455A1 (de) 1983-03-04 1984-09-06 Bayer Ag, 5090 Leverkusen Guanidin - derivate
DE3825867A1 (de) 1988-03-04 1989-09-14 Bayer Ag Heterocyclisch substituierte sulfonylaminoazole und ihre verwendung als herbizide
EP0409332A3 (en) 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
DE3928605A1 (de) 1989-08-30 1991-03-07 Bayer Ag Substituierte sulfonylaminoazole
WO1991011909A1 (fr) 1990-02-13 1991-08-22 Merck & Co., Inc. Antagonistes de triazole angiotensine ii incorporant un element de benzyle substitue
JPH0511439A (ja) 1990-09-13 1993-01-22 Fuji Photo Film Co Ltd 光重合性組成物
DE4035141A1 (de) 1990-11-06 1992-05-07 Bayer Ag Substituierte sulfonylaminotriazolylpyrimidine
SK278998B6 (sk) 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
SE9103397D0 (sv) 1991-11-18 1991-11-18 Kabi Pharmacia Ab Nya substituerade salicylsyror
DE69330713T2 (de) 1992-03-13 2002-07-04 Merck Sharp & Dohme Ltd., Hoddesdon Imidazol-, triazol- und tetrazolderivate
US5411839A (en) 1993-01-15 1995-05-02 Eastman Kodak Company Image formation in color reversal materials using strong inhibitors
CA2208603A1 (fr) 1995-02-03 1996-08-08 The Upjohn Company Phenyloxazolidinone substituee par un noyau heteroaromatique comme agent antimicrobien
US5563026A (en) 1995-04-28 1996-10-08 Eastman Kodak Company Color negative element having improved green record printer compatibility
JP3788676B2 (ja) 1997-11-11 2006-06-21 富士写真フイルム株式会社 有機エレクトロルミネツセンス素子材料およびそれを使用した有機エレクトロルミネツセンス素子
DK1054874T3 (da) 1998-02-13 2002-12-30 Upjohn Co Substituerede aminophenylisoxazolinderivater, der er anvendelige som antimokrobielle midler
WO1999046371A2 (fr) 1998-03-11 1999-09-16 Board Of Regents, The University Of Texas System Induction de l'expression de genes apoptotiques ou cytotoxiques par co-apport de genes a mediation adenovirale
BR0013899A (pt) 1999-09-10 2003-07-08 Merck & Co Inc Composto, composição farmacêutica, processos de tratamento ou prevenção de câncer, de uma doença em que a angiogênese esteja implicada, da vascularização retinal, da retinopatia diabética, da degeneração macular relacionada a idade, de doenças inflamatórias, de uma doença ou condições dependentes da tirosina quinase, de patologias associadas com ossos, e, processos para produzir uma composição farmacêutica, e de reduzir ou prevenir dano tecidual em seguida a um evento isquêmico cerebral
KR20030043785A (ko) 2000-03-16 2003-06-02 젠소프트, 인크. 핵산 결합 부위를 포함하는 하전된 화합물 및 이의 용도
AU2001242749A1 (en) 2000-03-23 2001-10-03 Takeda Chemical Industries Ltd. Peptide derivative
WO2001087855A1 (fr) 2000-05-19 2001-11-22 Yamanouchi Pharmaceutical Co., Ltd. Derives de triazole
WO2002053101A2 (fr) 2000-12-29 2002-07-11 Alteon, Inc. Procede de traitement de troubles fibrogenes et autres symptomes de type ivc
WO2002053160A1 (fr) 2000-12-29 2002-07-11 Alteon, Inc. Methode de traitement du glaucome ivb
US6787555B2 (en) 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6727364B2 (en) 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6790846B2 (en) 2001-05-24 2004-09-14 The Procter & Gamble Company Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity
JP2003005356A (ja) 2001-06-20 2003-01-08 Fuji Photo Film Co Ltd 電子線又はｘ線用ネガ型レジスト組成物
DE10138569A1 (de) 2001-08-06 2003-04-30 Bayer Ag Regulation des APJ-Rezeptors
JP2003321456A (ja) 2002-04-30 2003-11-11 Fuji Photo Film Co Ltd ５−アミノ−４−含窒素芳香族ヘテロ環置換ピラゾール類の製造方法
BR0313747A (pt) 2002-08-23 2005-06-21 Ribapharm Inc Inibidores de transcriptase reversa de não-nucleosìdeo
US7084145B2 (en) 2002-10-25 2006-08-01 Pfizer Inc. Triazole compounds useful in therapy
US7361669B2 (en) 2003-01-02 2008-04-22 Millennium Pharmaceuticals, Inc. Compositions and method for inhibiting TGF-β
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
JP2007524374A (ja) 2003-02-28 2007-08-30 プレキシコン，インコーポレーテッド Ｐｙｋ２結晶構造および使用
US20090048301A1 (en) 2003-07-09 2009-02-19 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
DE602004019548D1 (de) 2003-08-15 2009-04-02 Astrazeneca Ab Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
JP2007509045A (ja) 2003-10-18 2007-04-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 尿失禁および関連疾患の処置用のｇａｂａアゴニストとしての５−置換２−（フェニルメチル）チオ−４−フェニル−４ｈ−１，２，４−トリアゾール誘導体および関連化合物
JP2005170939A (ja) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
US20050165015A1 (en) 2004-01-23 2005-07-28 Ncube Mghele V. Vanilloid receptor ligands and their use in treatments
US7297168B2 (en) 2004-02-02 2007-11-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
DE102004008141A1 (de) 2004-02-19 2005-09-01 Abbott Gmbh & Co. Kg Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren
WO2005097758A1 (fr) 2004-03-26 2005-10-20 Amphora Discovery Corporation Composes et compositions a base de triazoles et leurs applications
JP2008502687A (ja) 2004-06-14 2008-01-31 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
US7399317B2 (en) 2004-08-26 2008-07-15 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
JP4882748B2 (ja) 2004-09-16 2012-02-22 アステラス製薬株式会社 トリアゾール誘導体またはその塩
EP2298748B1 (fr) 2004-11-18 2016-07-20 Synta Pharmaceuticals Corp. Composés triazole modulant l'activité de HSP90
US20060156480A1 (en) 2005-01-14 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
WO2006080533A1 (fr) 2005-01-31 2006-08-03 Mochida Pharmaceutical Co., Ltd. Dérivé de 3-amino-1,2,4-triazole
JP5044730B2 (ja) 2005-03-09 2012-10-10 日本化薬株式会社 新規なｈｓｐ９０阻害剤
EP1863484A1 (fr) 2005-03-21 2007-12-12 Pfizer Limited Derives de triazole substitues utilises en tant qu'antagonistes d'oxytocine
EP1870401A4 (fr) 2005-04-06 2011-06-15 Msd Kk Dérivé de substituée pipérazine en 1,4
WO2007007688A1 (fr) 2005-07-08 2007-01-18 Mochida Pharmaceutical Co., Ltd. Dérivé de 3,5-diamino-1,2,4-triazole
CA2620179C (fr) 2005-08-16 2013-10-29 Icagen, Inc. Inhibiteurs des canaux sodium sensibles au voltage
US8921406B2 (en) 2005-08-21 2014-12-30 AbbVie Deutschland GmbH & Co. KG 5-ring heteroaromatic compounds and their use as binding partners for 5-HT5 receptors
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
CN103121996B (zh) 2006-04-19 2015-10-21 默克雪兰诺有限公司 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物
TW200806637A (en) 2006-05-25 2008-02-01 Synta Pharmaceuticals Corp Synthesis of triazole compounds that modulate HSP90 activity
TW200804313A (en) 2006-05-25 2008-01-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
EP2034995A2 (fr) 2006-05-25 2009-03-18 Synta Pharmaceuticals Corporation Procédé pour traiter des troubles proliférants associés à des produits protooncogènes
AU2007267803B2 (en) 2006-05-25 2011-08-25 Synta Pharmaceuticals Corp. Method for treating non-Hodgkin's lymphoma
AU2012200157B2 (en) 2006-05-25 2014-08-21 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
CA2653329C (fr) 2006-05-25 2018-01-16 Synta Pharmaceuticals Corp. Composes de triazole modulant l'activite de hsp90
EP2038272B8 (fr) 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Inhibiteurs de pyridinonyle pdk1
ATE496905T1 (de) 2006-07-14 2011-02-15 Chemocentryx Inc Triazolyl-pyridyl-benzolsulfonamide als ccr2- oder ccr9-modulatoren zur behandlung von atherosklerose
US7718683B2 (en) 2006-07-14 2010-05-18 Chemocentryx, Inc. Triazolyl phenyl benzenesulfonamides
AU2007284537B2 (en) 2006-08-17 2012-04-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US20110046125A1 (en) 2006-10-19 2011-02-24 Synta Pharmaceuticals Corp. Method for treating infections
WO2008057246A2 (fr) 2006-10-26 2008-05-15 Synta Pharmaceuticals Corp. Procédé de traitement de troubles inflammatoires
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CN101679319B (zh) 2007-02-08 2014-07-09 辛塔医药品有限公司 用于治疗增生性病症如癌症的三唑类化合物
US7909187B2 (en) 2007-02-20 2011-03-22 Lonzell Montgomery Modular baby bottle system
US8993608B2 (en) 2007-03-12 2015-03-31 Synta Pharmaceuticals Corp. Method for inhibiting topoisomerase II
WO2008153730A2 (fr) 2007-05-25 2008-12-18 Synta Pharmaceuticals Corp. Méthode de traitement des maladies prolifératives associées à des mutations dans c-met
CN101801942B (zh) 2007-07-17 2013-03-27 美国艾森生物科学公司 杂环化合物和作为抗癌剂的用途
TWI438199B (zh) 2007-08-13 2014-05-21 Synta Pharmaceuticals Corp 調控ｈｓｐ９０活性的三唑化合物
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009075890A2 (fr) 2007-12-12 2009-06-18 Synta Pharmaceuticals Corp. Composés triazole qui modulent l'activité de hsp90
PE20091268A1 (es) 2007-12-19 2009-09-19 Amgen Inc Derivados heterociclicos como inhibidores de pi3 quinasa
DE102008013587A1 (de) 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
EP2103602A1 (fr) 2008-03-17 2009-09-23 AEterna Zentaris GmbH Nouveaux dérivés de triazole 1,2,4 et leur processus de fabrication
AU2009256390A1 (en) 2008-06-03 2009-12-10 Siga Technologies, Inc. Small molecule inhibitors for the treatment or prevention of dengue virus infection
JP5615274B2 (ja) 2008-07-01 2014-10-29 ジェネンテック， インコーポレイテッド Ｍｅｋキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法
WO2010003025A1 (fr) 2008-07-01 2010-01-07 Genentech, Inc. Hétérocycles bicycliques en tant qu'inhibiteurs de mek kinase
EP2323737A2 (fr) 2008-08-08 2011-05-25 Synta Pharmaceuticals Corp. Composés de triazole qui modulent l'activité hsp90
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
EP2367554A4 (fr) 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Inhibiteurs de recyclage de l'acide biliaire pour le traitement de l'obésité et du diabète
DE102008059702A1 (de) 2008-12-01 2010-06-02 Byk-Chemie Gmbh Verfahren zur Herstellung rheologisch wirksamer Harnstoffurethane in organischen Salzen
AU2010255552A1 (en) 2009-06-05 2012-01-12 Oslo University Hospital Hf Azole derivatives as Wtn pathway inhibitors
US20120238576A1 (en) 2009-06-08 2012-09-20 California Capital Equity, Llc Triazine Derivatives and their Therapeutical Applications
WO2011071565A1 (fr) 2009-12-11 2011-06-16 Exelixis, Inc. Agonistes de tgr5
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
WO2011133521A2 (fr) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Traitement anticancéreux utilisant une combinaison de composés inhibiteurs de hsp90 et un inhibiteur de vegf
EP2560640A1 (fr) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Thérapie anticancéreuse à l'aide d'une combinaison d'un composé inhibiteur de hsp90 et d'un inhibiteur d'egfr
US20130172333A1 (en) 2010-05-20 2013-07-04 Synta Pharmaceuticals Corp. Formulation and dosing of hsp90 inhibitory compounds
EP3593802A3 (fr) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Inhibiteurs de recyclage d'acide biliaire et satiogènes pour le traitement du diabète, de l'obésité et des conditions gastro-intestinales inflammatoires
BR112013000925A2 (pt) 2010-07-15 2020-12-01 Bayer Intellectual Property Gmbh compostos heterocíclicos como pesticidas
WO2012021778A2 (fr) 2010-08-12 2012-02-16 The Regents Of The University Of California Procédés de blocage de la prolifération cellulaire et de traitement de maladies et d'affections répondant à une inhibition de la croissance cellulaire
WO2012076898A1 (fr) 2010-12-08 2012-06-14 Oslo University Hospital Hf Dérivés de triazole en tant qu'inhibiteurs de la voie de signalisation wnt
WO2012116247A1 (fr) 2011-02-25 2012-08-30 Synta Pharmaceuticals Corp. Composés inhibiteurs de hsp90 dans le traitement de cancers à médiation par la signalisation jak/stat
CA2842707A1 (fr) 2011-08-04 2013-02-07 Lumena Pharmaceuticals, Inc. Inhibiteurs du recyclage de l'acide biliaire dans le traitement du pancreas
US9593109B2 (en) 2011-08-26 2017-03-14 Cymabay Therapeutics, Inc. Bicyclic agonists of GPR131 and uses thereof
KR102051031B1 (ko) 2011-10-28 2019-12-02 루메나 파마수티컬즈, 인코포레이티드 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
BR112014010223B8 (pt) 2011-10-28 2021-02-23 Lumena Pharmaceuticals Llc uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
WO2013067162A1 (fr) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Thérapie anticancéreuse utilisant une combinaison d'inhibiteurs de hsp 90 et d'inhibiteurs de topoisomérase i
EP2780010A1 (fr) 2011-11-14 2014-09-24 Synta Pharmaceuticals Corp. Association thérapeutique d'inhibiteurs de hsp90 et d'inhibiteurs de braf
EP2802596A1 (fr) 2012-01-09 2014-11-19 Anchor Therapeutics, Inc. Composés de récepteurs apj
CN104169275B (zh) 2012-01-13 2017-06-09 百时美施贵宝公司 用作激酶抑制剂的三唑取代的吡啶化合物
AU2013239663A1 (en) 2012-03-28 2014-10-09 Synta Pharmaceuticals Corp. Triazole derivatives as HSP90 inhibitors
CA2875964C (fr) 2012-06-07 2018-01-02 Georgia State University Research Foundation, Inc. Inhibiteurs de seca et leurs procedes de fabrication et d'utilisation
US20140005181A1 (en) 2012-06-21 2014-01-02 Sanford-Burnham Medical Research Institute Small molecule antagonists of the apelin receptor for the treatment of disease
ES2623528T3 (es) 2012-09-21 2017-07-11 Sanofi Derivados de amida de ácido benzoimidazolcarboxílico para tratar enfermedades metabólicas o cardiovasculares
JP6426107B2 (ja) 2012-12-20 2018-11-21 アムジエン・インコーポレーテツド Ａｐｊ受容体アゴニストおよびその使用
JP2016512825A (ja) 2013-03-15 2016-05-09 シファ・バイオメディカル・コーポレイションＳｈｉｆａ Ｂｉｏｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 抗プロタンパク質転換酵素サブチリシン／ケキシン９型（抗ｐｃｓｋ９）化合物および心血管疾患の治療および／または予防におけるその使用方法
UY35517A (es) 2013-04-04 2014-10-31 Mabxience S A Un procedimiento para aumentar la formación de ácido piroglutamico de una proteína
CN111423479A (zh) 2013-05-30 2020-07-17 华盛顿大学 用于治疗细菌性感染的化合物和方法
WO2015140296A2 (fr) 2014-03-20 2015-09-24 Centre National De La Recherche Scientifique (Cnrs) Utilisation de composés inhibant la signalisation d'apeline/apj/gp130 pour le traitement du cancer
CN106459160B (zh) 2014-04-24 2022-03-29 南洋理工大学 Asx特异性蛋白质连接酶
WO2015184011A2 (fr) 2014-05-28 2015-12-03 Sanford-Burnham Medical Research Institute Agonistes du récepteur de l'apéline et leurs procédés d'utilisation
PE20170664A1 (es) 2014-06-06 2017-06-10 Res Triangle Inst Agonistas del receptor de apelina(apj) y usos de los mismos
US20160058705A1 (en) 2014-08-28 2016-03-03 Jayakumar Rajadas Compositions and methods for treating cardiovascular and pulmonary diseases and disorders with apelin
US20170355734A1 (en) 2014-12-23 2017-12-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Metabolically Stable Apelin Analogs in the Treatment of Disease Mediated by the Apelin Receptor
WO2016151018A1 (fr) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode et composition pharmaceutique destinées à être utilisées dans le traitement du diabète
US10647689B2 (en) 2015-04-28 2020-05-12 Sanford Burnham Prebys Medical Discovery Institute Apelin receptor agonists and methods of use thereof
AU2016263564B2 (en) 2015-05-20 2019-12-05 Amgen Inc. Triazole agonists of the APJ receptor
CA2988147C (fr) 2015-06-03 2023-06-13 Bristol-Myers Squibb Company Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
PE20181197A1 (es) 2015-10-14 2018-07-23 Bristol Myers Squibb Co 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
EP3380970B1 (fr) 2015-11-24 2023-01-04 Sanford Burnham Prebys Medical Discovery Institute Nouveaux dérivés azolés comme agoniste du récepteur de l'apéline
BR112018010720A8 (pt) 2015-12-04 2019-02-26 Bristol Myers Squibb Co agonistas do receptor de apelina e métodos de uso
PE20190258A1 (es) 2015-12-09 2019-02-25 Res Triangle Inst Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos
US9989592B2 (en) 2015-12-18 2018-06-05 Intel IP Corporation Interfaces for wireless debugging
TWI744301B (zh) 2016-03-24 2021-11-01 美商必治妥美雅史谷比公司 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺
EP3228630A1 (fr) 2016-04-07 2017-10-11 IMBA-Institut für Molekulare Biotechnologie GmbH Combinaison d'un antagoniste d'apeline et inhibiteur de l'angiogenèse pour le traitement du cancer
US9988369B2 (en) 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor
ES2844184T3 (es) 2016-06-14 2021-07-21 Bristol Myers Squibb Co 4-hidroxi-3-sulfonilpiridin-2(1H)-onas como agonistas del receptor de APJ
WO2017218633A1 (fr) 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 6-hydroxy-5-(phényl/hétéroarylsulfonyl) pyrimidin-4(1h)-one utilisée en tant qu'agonistes de l'apj
PE20190806A1 (es) 2016-10-12 2019-06-10 Res Triangle Inst Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos
CN110072850B (zh) 2016-10-14 2023-07-21 百时美施贵宝公司 3-磺酰基-5-氨基吡啶-2,4-二醇apj激动剂
WO2018093577A1 (fr) 2016-11-16 2018-05-24 Amgen Inc. Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
WO2018097944A1 (fr) 2016-11-16 2018-05-31 Amgen Inc. Composés de triazole furane utilisés en tant qu'agonistes du récepteur apj
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
US10689367B2 (en) * 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
US20190276696A1 (en) 2016-11-23 2019-09-12 Guangzhou Chinaray Optoelectronic Materials Ltd. Formulations for printed electronic devices, preparation methods and uses thereof

Also Published As

Publication number Publication date
US11149040B2 (en) 2021-10-19
EP3704122A1 (fr) 2020-09-09
WO2019089335A1 (fr) 2019-05-09
US20200308189A1 (en) 2020-10-01
EP3704122B1 (fr) 2021-09-01

Similar Documents

Publication Publication Date Title
EP4069686C0 (fr) Agoniste du récepteur glp-1
IL288921A (en) Melanocortin-4 receptor agonists
DK3762380T3 (da) Phenylpyrrolidinon-formylpeptid-2-receptoragonister
IL272274A (en) B7-h4 antibodies and methods of use thereof
ZA201707706B (en) Triazole agonists of the apj receptor
DK3368060T3 (da) Glugacon-receptor-agonister
CL2018000920A1 (es) Conjugados de anticuerpos que comprenden agonistas de receptor similares
EP3849598A4 (fr) Anticorps agonistes anti-trem-2
IL259947B (en) Heteroarylhydroxypyrimidinones as agonists of the apj receptor
PT3494133T (pt) Recetores de células t anti-kras-g12d
EP3521427A4 (fr) Co-récepteur de récepteur odorant
HUE047929T2 (hu) Kiméra antigén receptor
DK3283110T3 (da) Antistoffer rettet mod interleukin-36-receptor (il-36r)
IL258502A (en) Chimeric antigen receptors targeted to psca
EP3630078A4 (fr) Agents pour chimio-embolisation
DK3649152T3 (da) ROR1-antistoffer
EP3695547C0 (fr) Signal de référence de suivi de phase
EP3604344A4 (fr) Récepteur antigénique chimérique
DK3713928T3 (da) Hidtil ukendte bradykinin-b2-receptorantagonister
LT3684813T (lt) Agonistiniai cd40 antikūnai
EP3841085A4 (fr) Test pour nbome
EP3440051A4 (fr) Agonistes du récepteur du neuropeptide s (npsr)
IT201800003973A1 (it) Dispositivo per la fusione interspinosa
GB201619637D0 (en) C3a receptor agonists
MA46464A (fr) Polymorphes de l'agoniste de récepteur muscarinique